Arbor Pharmaceuticals v. Alkem Laboratories: Dismissed Without Prejudice After 701 Days
Arbor Pharmaceuticals and Azurity Pharmaceuticals filed suit against Alkem Laboratories in the District of New Jersey, asserting two patents covering non-aqueous liquid nimodipine compositions. After 701 days of litigation, all claims and counterclaims were dismissed without prejudice.
Nimodipine Composition Patents: A Two-Year Dispute Left Open
Arbor Pharmaceuticals LLC and Azurity Pharmaceuticals Inc. jointly filed this infringement action on 11 January 2022 in the United States District Court for the District of New Jersey. The suit named Alkem Laboratories Ltd. as defendant and asserted two patents — US10576070B2 and US10342787B1 — both covering non-aqueous liquid nimodipine compositions, a formulation space of significant commercial interest in the treatment of subarachnoid hemorrhage.
The recorded Basis of Termination is 'Dismissed without Prejudice.' The docket order states that all claims and counterclaims asserted in the above-captioned action are hereby dismissed without prejudice. A dismissal without prejudice does not constitute a final adjudication on the merits and preserves the plaintiffs' ability to refile the same claims, subject to applicable procedural and statutory constraints.
The case ran for 701 days before closing on 13 December 2023, a duration that suggests substantive activity well beyond early procedural stages — though the specific drivers of the resolution are not disclosed in the available record. What prompted the without-prejudice dismissal rather than a merits ruling or consent judgment remains unknown from the public record. The two asserted patents remain a relevant consideration for any party operating in the non-aqueous liquid nimodipine formulation space.
See Complete Case & Patent Analysis →Filing to Dismissed without Prejudice in 701 days
701 days from filing to dismissal in the District of New Jersey
US10576070B2 & US10342787B1 — Non-Aqueous Liquid Nimodipine Compositions
Any company developing, manufacturing, or seeking regulatory approval for a non-aqueous liquid nimodipine product — including ANDA filers, 505(b)(2) applicants, and contract development organisations — should conduct a freedom-to-operate analysis against both US10576070B2 and US10342787B1. The without-prejudice dismissal of this case means neither patent has been invalidated or found not infringed by a court. Enforcement risk against new entrants remains live.
Official order — verbatim text
The dismissal order extinguishes all pending claims and counterclaims in this action without a merits determination. Because the dismissal is expressly without prejudice, neither the validity nor the infringement of US10576070B2 or US10342787B1 has been adjudicated, and the order does not function as a bar to future proceedings on the same patents.
Dismissed without prejudice: what the ruling means for both parties
Dismissal without prejudice leaves the door open
A dismissal without prejudice terminates the current proceeding but does not bar the plaintiffs from refiling the same claims in a future action, provided applicable statutes of limitations and procedural rules permit. No merits adjudication was made: no court found the patents valid, invalid, infringed, or not infringed. The specific terms or conditions underlying this dismissal are not disclosed in the available record.
No merits rulingPlaintiffs retain the right to refile
Arbor Pharmaceuticals and Azurity Pharmaceuticals exit this proceeding without a finding against their patents. US10576070B2 and US10342787B1 have not been adjudicated invalid or not infringed, meaning the patents remain enforceable on their face. The plaintiffs retain the option to refile against Alkem or assert these patents against other parties in future proceedings. What drove the decision to dismiss rather than proceed to judgment is not disclosed.
Patents remain enforceableAlkem avoids a merits ruling — for now
Alkem Laboratories exits this action without a court finding of non-infringement or invalidity that it could rely on as a shield in future proceedings. Because the dismissal is without prejudice, the threat of re-litigation over the same nimodipine composition patents persists. Alkem's counterclaims, if any were asserted, were equally dismissed without prejudice under the same order.
Future exposure remainsUncertainty persists in the nimodipine formulation space
Generic and specialty pharma companies operating in the non-aqueous liquid nimodipine segment should note that the enforceability question around US10576070B2 and US10342787B1 remains unresolved. A without-prejudice dismissal signals that this IP may be reasserted. Companies considering ANDA filings or product launches in this category should factor ongoing patent risk into their FTO and regulatory strategies.
Monitor for refilingFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Arbor Pharmaceuticals, LLC | Company | /Search in Eureka ↗ |
| Co-Plaintiff | Azurity Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Defendant | Alkem Laboratories, Ltd. | Company | /Search in Eureka ↗ |
| Plaintiff counsel | Arnold B. Calmann | Attorney | Counsel for Arbor Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Katherine Ann Escanlar | Attorney | Counsel for Arbor Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Saiber LLC | Law Firm | Representing Arbor Pharmaceuticals, LLCSearch in Eureka ↗ |
| Defendant counsel | Gene Y. Kang | Attorney | Counsel for Alkem Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Gregory D. Miller | Attorney | Counsel for Alkem Laboratories, Ltd.Search in Eureka ↗ |
| Defendant law firm | Rivkin Radler LLP | Law Firm | Representing Alkem Laboratories, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
R&D signals in the non-aqueous nimodipine formulation space
Patent and innovation intelligence derived from this case — tracking Arbor, Azurity, and Alkem's IP posture in liquid CNS drug formulation.
Arbor & Azurity's nimodipine IP filing activity
Arbor Pharmaceuticals and Azurity Pharmaceuticals' assertion of two overlapping nimodipine composition patents suggests an active continuation strategy. Mapping their broader portfolio — including pending applications, continuations-in-part, and related family members — can reveal the full claim perimeter around non-aqueous liquid nimodipine and identify whether new barriers are being erected in adjacent formulation approaches.
Continuation watchFiling trends in liquid CNS drug formulation patents
The non-aqueous liquid delivery format for CNS drugs — particularly calcium channel blockers — is an area of active formulation innovation. Tracking patent filing trends in non-aqueous liquid pharmaceutical compositions for CNS indications can surface emerging competitive technologies, alternative solvent systems, and novel excipient combinations that may inform design-around strategies or new product development opportunities.
Liquid CNS formulation trendsAlkem Laboratories' formulation IP position
Alkem Laboratories is a significant generic pharmaceutical manufacturer. Analysing Alkem's own patent filings in pharmaceutical formulation — particularly liquid and non-aqueous compositions — can reveal whether it is developing proprietary formulation IP that could support future product differentiation or defensive positioning in the nimodipine or related CNS drug space.
Generic pharma IP strategyAdjacent formulation white space near the asserted patents
With core nimodipine compound patents expired and formulation patents actively enforced, adjacent white space may exist in delivery mechanisms not covered by US10576070B2 or US10342787B1 — such as alternative non-aqueous solvent systems, novel excipients, or modified-release approaches. A targeted prior art and claim gap analysis could identify patentable or freedom-to-operate corridors for new entrants in this space.
Formulation white spaceSimilar Hatch-Waxman Patent Cases in the NJ District Court
Explore comparable pharmaceutical formulation patent infringement actions in the District of New Jersey, particularly involving non-aqueous or liquid drug composition patents and ANDA disputes.
What this case signals for the nimodipine and specialty pharma IP landscape
An unresolved without-prejudice dismissal leaves two nimodipine composition patents in play — a meaningful signal for generic entrants and formulators.
Without-prejudice exits preserve enforcement leverage for patent holders
Arbor and Azurity retain full ability to refile. Companies developing or commercialising non-aqueous liquid nimodipine formulations should treat US10576070B2 and US10342787B1 as active enforcement risks. An FTO analysis against both patents is advisable before any product launch or ANDA submission in this space.
Generic entrants face residual litigation risk despite case closure
Alkem's dismissal without a non-infringement or invalidity finding means no publicly recorded shield exists. Other generic manufacturers targeting this formulation category face similar exposure. Monitoring the plaintiffs' docketing activity for refiling or new assertions against other defendants is a prudent competitive intelligence step.
Arbor v Alkem — key questions answered
The plaintiffs — Arbor Pharmaceuticals LLC and Azurity Pharmaceuticals Inc. — asserted two patents: US10576070B2 (application US16/407980) and US10342787B1 (application US15/954357). Both patents cover non-aqueous liquid nimodipine compositions.
The case was dismissed without prejudice on 13 December 2023, after 701 days of litigation. The docket order states that all claims and counterclaims asserted in the action are hereby dismissed without prejudice. No merits adjudication was made. The specific terms or reasons for the dismissal are not disclosed in the available record.
No. A dismissal without prejudice carries no merits determination. Neither US10576070B2 nor US10342787B1 was found invalid, unenforceable, or not infringed by this order. Both patents remain enforceable on their face, and the plaintiffs retain the ability to refile claims subject to applicable procedural rules.
A dismissal without prejudice generally preserves the plaintiff's right to refile the same claims in a future action, subject to applicable statutes of limitations and procedural rules. Whether and when the plaintiffs may exercise that right is not determinable from the current public record.
Because nimodipine's compound patent protection has expired, formulation patents such as US10576070B2 and US10342787B1 are the primary IP mechanism protecting branded non-aqueous liquid nimodipine products. Generic manufacturers filing ANDAs or 505(b)(2) applications for this product category must conduct FTO analyses against these patents. The unresolved status of this case means enforcement risk remains active.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.